Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

BACKGROUND: Tafolecimab is a novel fully human proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody, developed for the treatment of hypercholesterolemia. OBJECTIVES: The purpose of this study was to assess the efficacy and safety of tafolecimab in Chinese patients at high or ver...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Litong, Liu, Dexue, Qu, Yanling, Chen, Beijian, Meng, Haiyan, Zhu, Lei, Li, Lipeng, Wang, Shuqing, Liu, Changyi, Zheng, Guanzhong, Lian, Qiufang, Yin, Guotian, Lv, Lingchun, Lu, Di, Chen, Xiaoshu, Xue, Fengtai, An, Pei, Li, Haoyu, Deng, Huan, Li, Li, Qian, Lei, Huo, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442872/
https://www.ncbi.nlm.nih.gov/pubmed/37614541
http://dx.doi.org/10.1016/j.jacasi.2023.04.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442872/
https://www.ncbi.nlm.nih.gov/pubmed/37614541
http://dx.doi.org/10.1016/j.jacasi.2023.04.011

Ejemplares similares